Cargando…

Knockout of the CMP–Sialic Acid Transporter SLC35A1 in Human Cell Lines Increases Transduction Efficiency of Adeno-Associated Virus 9: Implications for Gene Therapy Potency Assays

Recombinant adeno-associated viruses (AAV) have emerged as an important tool for gene therapy for human diseases. A prerequisite for clinical approval is an in vitro potency assay that can measure the transduction efficiency of each virus lot produced. The AAV serotypes are typical for gene therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Banning, Antje, Zakrzewicz, Anna, Chen, Xin, Gray, Steven J., Tikkanen, Ritva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160606/
https://www.ncbi.nlm.nih.gov/pubmed/34069698
http://dx.doi.org/10.3390/cells10051259
_version_ 1783700317591830528
author Banning, Antje
Zakrzewicz, Anna
Chen, Xin
Gray, Steven J.
Tikkanen, Ritva
author_facet Banning, Antje
Zakrzewicz, Anna
Chen, Xin
Gray, Steven J.
Tikkanen, Ritva
author_sort Banning, Antje
collection PubMed
description Recombinant adeno-associated viruses (AAV) have emerged as an important tool for gene therapy for human diseases. A prerequisite for clinical approval is an in vitro potency assay that can measure the transduction efficiency of each virus lot produced. The AAV serotypes are typical for gene therapy bind to different cell surface structures. The binding of AAV9 on the surface is mediated by terminal galactose residues present in the asparagine-linked carbohydrates in glycoproteins. However, such terminal galactose residues are rare in cultured cells. They are masked by sialic acid residues, which is an obstacle for the infection of many cell lines with AAV9 and the respective potency assays. The sialic acid residues can be removed by enzymatic digestion or chemical treatment. Still, such treatments are not practical for AAV9 potency assays since they may be difficult to standardize. In this study, we generated human cell lines (HEK293T and HeLa) that become permissive for AAV9 transduction after a knockout of the CMP–sialic acid transporter SLC35A1. Using the human aspartylglucosaminidase (AGA) gene, we show that these cell lines can be used as a model system for establishing potency assays for AAV9-based gene therapy approaches for human diseases.
format Online
Article
Text
id pubmed-8160606
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81606062021-05-29 Knockout of the CMP–Sialic Acid Transporter SLC35A1 in Human Cell Lines Increases Transduction Efficiency of Adeno-Associated Virus 9: Implications for Gene Therapy Potency Assays Banning, Antje Zakrzewicz, Anna Chen, Xin Gray, Steven J. Tikkanen, Ritva Cells Article Recombinant adeno-associated viruses (AAV) have emerged as an important tool for gene therapy for human diseases. A prerequisite for clinical approval is an in vitro potency assay that can measure the transduction efficiency of each virus lot produced. The AAV serotypes are typical for gene therapy bind to different cell surface structures. The binding of AAV9 on the surface is mediated by terminal galactose residues present in the asparagine-linked carbohydrates in glycoproteins. However, such terminal galactose residues are rare in cultured cells. They are masked by sialic acid residues, which is an obstacle for the infection of many cell lines with AAV9 and the respective potency assays. The sialic acid residues can be removed by enzymatic digestion or chemical treatment. Still, such treatments are not practical for AAV9 potency assays since they may be difficult to standardize. In this study, we generated human cell lines (HEK293T and HeLa) that become permissive for AAV9 transduction after a knockout of the CMP–sialic acid transporter SLC35A1. Using the human aspartylglucosaminidase (AGA) gene, we show that these cell lines can be used as a model system for establishing potency assays for AAV9-based gene therapy approaches for human diseases. MDPI 2021-05-19 /pmc/articles/PMC8160606/ /pubmed/34069698 http://dx.doi.org/10.3390/cells10051259 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Banning, Antje
Zakrzewicz, Anna
Chen, Xin
Gray, Steven J.
Tikkanen, Ritva
Knockout of the CMP–Sialic Acid Transporter SLC35A1 in Human Cell Lines Increases Transduction Efficiency of Adeno-Associated Virus 9: Implications for Gene Therapy Potency Assays
title Knockout of the CMP–Sialic Acid Transporter SLC35A1 in Human Cell Lines Increases Transduction Efficiency of Adeno-Associated Virus 9: Implications for Gene Therapy Potency Assays
title_full Knockout of the CMP–Sialic Acid Transporter SLC35A1 in Human Cell Lines Increases Transduction Efficiency of Adeno-Associated Virus 9: Implications for Gene Therapy Potency Assays
title_fullStr Knockout of the CMP–Sialic Acid Transporter SLC35A1 in Human Cell Lines Increases Transduction Efficiency of Adeno-Associated Virus 9: Implications for Gene Therapy Potency Assays
title_full_unstemmed Knockout of the CMP–Sialic Acid Transporter SLC35A1 in Human Cell Lines Increases Transduction Efficiency of Adeno-Associated Virus 9: Implications for Gene Therapy Potency Assays
title_short Knockout of the CMP–Sialic Acid Transporter SLC35A1 in Human Cell Lines Increases Transduction Efficiency of Adeno-Associated Virus 9: Implications for Gene Therapy Potency Assays
title_sort knockout of the cmp–sialic acid transporter slc35a1 in human cell lines increases transduction efficiency of adeno-associated virus 9: implications for gene therapy potency assays
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160606/
https://www.ncbi.nlm.nih.gov/pubmed/34069698
http://dx.doi.org/10.3390/cells10051259
work_keys_str_mv AT banningantje knockoutofthecmpsialicacidtransporterslc35a1inhumancelllinesincreasestransductionefficiencyofadenoassociatedvirus9implicationsforgenetherapypotencyassays
AT zakrzewiczanna knockoutofthecmpsialicacidtransporterslc35a1inhumancelllinesincreasestransductionefficiencyofadenoassociatedvirus9implicationsforgenetherapypotencyassays
AT chenxin knockoutofthecmpsialicacidtransporterslc35a1inhumancelllinesincreasestransductionefficiencyofadenoassociatedvirus9implicationsforgenetherapypotencyassays
AT graystevenj knockoutofthecmpsialicacidtransporterslc35a1inhumancelllinesincreasestransductionefficiencyofadenoassociatedvirus9implicationsforgenetherapypotencyassays
AT tikkanenritva knockoutofthecmpsialicacidtransporterslc35a1inhumancelllinesincreasestransductionefficiencyofadenoassociatedvirus9implicationsforgenetherapypotencyassays